Historical Revenue GrowthMulti-year revenue expansion from 2020–2025 indicates durable demand and successful commercial execution. Sustained top-line growth supports scale economics, capacity utilization and reinvestment for R&D or production, strengthening long-term competitive position and market share resilience.

Stable Balance SheetA generally sound equity base with moderate leverage gives financial flexibility to fund operations and withstand industry cycles. Manageable debt levels reduce refinancing risk and support capital allocation for capacity, regulatory compliance and strategic investments over the medium term.

Recovering Operating Cash FlowRecovered operating cash flow demonstrates the core business can generate cash from operations, enabling working-capital management and basic reinvestment. Over 2–6 months this supports operational continuity and reduces immediate reliance on external financing for routine needs.

Bears Say

Margin CompressionRecent compression in gross and net margins signals pressure on pricing, input costs or product mix. Persistently thinner margins erode ability to fund R&D, capex and commercial expansion, harming long-term competitiveness and leaving the business more vulnerable to cost shocks or pricing pressure.

Volatile Free Cash FlowVolatile and recently negative free cash flow constrains reinvestment, debt reduction and shareholder returns. Over a multi-month horizon this raises liquidity risk, increases dependence on external funding and limits the firm’s ability to pursue strategic opportunities or absorb operational setbacks.

Rising Leverage RiskA declining equity ratio and modestly higher leverage reduce financial flexibility and increase interest and refinancing exposure. If sustained, higher leverage can restrict strategic options, raise funding costs and magnify earnings volatility during downturns, weighing on medium-term resilience.

Bafna Pharmaceuticals Limited News

Bafna Pharmaceuticals Files SEBI Dematerialisation Compliance Certificate for Q3 FY2025

Bafna Pharmaceuticals Limited ( ($IN:BAFNAPH) ) has shared an update. Bafna Pharmaceuticals Limited has submitted to the stock...

2M ago

Bafna Pharmaceuticals Completes Sale of Chennai Manufacturing Unit

An update from Bafna Pharmaceuticals Limited ( ($IN:BAFNAPH) ) is now available. Bafna Pharmaceuticals Limited has completed the...

9M ago

Bafna Pharmaceuticals Submits Annual SEBI Disclosure

Bafna Pharmaceuticals Limited ( ($IN:BAFNAPH) ) has shared an update. Bafna Pharmaceuticals Limited has submitted its annual disclosure...

9M ago

Bafna Pharmaceuticals Announces Board and Committee Restructuring

The latest update is out from Bafna Pharmaceuticals Limited ( ($IN:BAFNAPH) ). Bafna Pharmaceuticals Limited announced the retirement...

9M ago

BAFNAPH FAQ

What was Bafna Pharmaceuticals Limited’s price range in the past 12 months?

Bafna Pharmaceuticals Limited lowest stock price was ₹71.65 and its highest was ₹204.95 in the past 12 months.

What is Bafna Pharmaceuticals Limited’s market cap?

Bafna Pharmaceuticals Limited’s market cap is ₹2.32B.

When is Bafna Pharmaceuticals Limited’s upcoming earnings report date?

Bafna Pharmaceuticals Limited’s upcoming earnings report date is Jun 03, 2026 which is in 79 days.

How were Bafna Pharmaceuticals Limited’s earnings last quarter?

Bafna Pharmaceuticals Limited released its earnings results on Feb 11, 2026. The company reported ₹0.776 earnings per share for the quarter, beating the consensus estimate of N/A by ₹0.776.

Is Bafna Pharmaceuticals Limited overvalued?

According to Wall Street analysts Bafna Pharmaceuticals Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Bafna Pharmaceuticals Limited pay dividends?

Bafna Pharmaceuticals Limited pays a Notavailable dividend of ₹0.6 which represents an annual dividend yield of N/A. See more information on Bafna Pharmaceuticals Limited dividends here

What is Bafna Pharmaceuticals Limited’s EPS estimate?

Bafna Pharmaceuticals Limited’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Bafna Pharmaceuticals Limited have?

Bafna Pharmaceuticals Limited has 23,656,336 shares outstanding.

What happened to Bafna Pharmaceuticals Limited’s price movement after its last earnings report?

Bafna Pharmaceuticals Limited reported an EPS of ₹0.776 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 1.563%.

Which hedge fund is a major shareholder of Bafna Pharmaceuticals Limited?

Currently, no hedge funds are holding shares in IN:BAFNAPH

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Bafna Pharmaceuticals Limited

Bafna Pharmaceuticals Limited manufactures and sells finished pharmaceutical formulations in India. The company provides delayed and sustained release, chewable, and orally disintegrating tablets. It also exports its products. Bafna Pharmaceuticals Limited was founded in 1981 and is based in Chennai, India.